The purpose of this study is to find out if people with rheumatoid arthritis and interstitial lung disease (ILD) can benefit from taking Pirfenidone.
Our researchers also want to determine if the medication can be taken safely without many side effects. Pirfenidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). This study will compare the results of taking Pirfenidone to those of a placebo, a medication that looks like Pirfenidone but does not contain the drug. Participants may receive Pirfenidone or a placebo.